Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).

Fellows P, Adamovicz J, Hartings J, Sherwood R, Mega W, Brasel T, Barr E, Holland L, Lin W, Rom A, Blackwelder W, Price J, Morris S, Snow D, Hart MK.

Vaccine. 2010 Nov 16;28(49):7748-56. doi: 10.1016/j.vaccine.2010.09.062. Epub 2010 Oct 15.

PMID:
20920572
2.

Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.

Williamson ED, Flick-Smith HC, Waters E, Miller J, Hodgson I, Le Butt CS, Hill J.

Microb Pathog. 2007 Jan;42(1):11-21. Epub 2006 Nov 14.

PMID:
17107769
3.

Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy.

Fellows P, Price J, Martin S, Metcalfe K, Krile R, Barnewall R, Hart MK, Lockman H.

Clin Vaccine Immunol. 2015 Sep;22(9):1070-8. doi: 10.1128/CVI.00290-15. Epub 2015 Jul 29.

4.

Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.

Williamson ED, Packer PJ, Waters EL, Simpson AJ, Dyer D, Hartings J, Twenhafel N, Pitt ML.

Vaccine. 2011 Jun 24;29(29-30):4771-7. doi: 10.1016/j.vaccine.2011.04.084. Epub 2011 May 12.

PMID:
21570437
5.
6.

Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.

Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, Ciletti NA, Schneewind O.

Infect Immun. 2008 Dec;76(12):5588-97. doi: 10.1128/IAI.00699-08. Epub 2008 Sep 15.

7.

Efficacy of primate humoral passive transfer in a murine model of pneumonic plague is mouse strain-dependent.

Graham VA, Hatch GJ, Bewley KR, Steeds K, Lansley A, Bate SR, Funnell SG.

J Immunol Res. 2014;2014:807564. doi: 10.1155/2014/807564. Epub 2014 Jul 6.

8.

Protective efficacy of a fully recombinant plague vaccine in the guinea pig.

Jones SM, Griffin KF, Hodgson I, Williamson ED.

Vaccine. 2003 Sep 8;21(25-26):3912-8.

PMID:
12922126
9.

T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.

Levy Y, Flashner Y, Tidhar A, Zauberman A, Aftalion M, Lazar S, Gur D, Shafferman A, Mamroud E.

Vaccine. 2011 Sep 16;29(40):6866-73. doi: 10.1016/j.vaccine.2011.07.059. Epub 2011 Jul 29.

PMID:
21803090
10.

Development of a recombinant vaccine against aerosolized plague.

Morris SR.

Vaccine. 2007 Apr 20;25(16):3115-7. Epub 2007 Jan 30.

PMID:
17291640
11.
12.

Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.

Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.

Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6.

PMID:
18304706
13.

Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta.

Qiu Y, Liu Y, Qi Z, Wang W, Kou Z, Zhang Q, Liu G, Liu T, Yang Y, Yang X, Xin Y, Li C, Cui B, Huang S, Liu H, Zeng L, Wang Z, Yang R, Wang H, Wang X.

Scand J Immunol. 2010 Nov;72(5):425-33. doi: 10.1111/j.1365-3083.2010.02456.x.

14.

A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Sha J, Kirtley ML, Klages C, Erova TE, Telepnev M, Ponnusamy D, Fitts EC, Baze WB, Sivasubramani SK, Lawrence WS, Patrikeev I, Peel JE, Andersson JA, Kozlova EV, Tiner BL, Peterson JW, McWilliams D, Patel S, Rothe E, Motin VL, Chopra AK.

Clin Vaccine Immunol. 2016 Jul 5;23(7):586-600. doi: 10.1128/CVI.00150-16. Print 2016 Jul.

15.

Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.

Anderson GW Jr, Heath DG, Bolt CR, Welkos SL, Friedlander AM.

Am J Trop Med Hyg. 1998 Jun;58(6):793-9.

PMID:
9660466
16.

A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague.

Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW.

Vaccine. 1997 Jul;15(10):1079-84.

PMID:
9269050
17.

Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization.

Hill J, Leary SE, Griffin KF, Williamson ED, Titball RW.

Infect Immun. 1997 Nov;65(11):4476-82.

18.

Plague vaccines and the molecular basis of immunity against Yersinia pestis.

Quenee LE, Schneewind O.

Hum Vaccin. 2009 Dec;5(12):817-23. Epub 2009 Dec 1. Review.

PMID:
19786842
19.

Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.

Qi Z, Zhou L, Zhang Q, Ren L, Dai R, Wu B, Wang T, Zhu Z, Yang Y, Cui B, Wang Z, Wang H, Qiu Y, Guo Z, Yang R, Wang X.

Vaccine. 2010 Feb 10;28(6):1655-60. doi: 10.1016/j.vaccine.2009.02.078. Epub 2009 Mar 9.

PMID:
20079562
20.

Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.

Kumar D, Kirimanjeswara G, Metzger DW.

Clin Vaccine Immunol. 2011 Nov;18(11):1925-35. doi: 10.1128/CVI.05117-11. Epub 2011 Aug 31.

Supplemental Content

Support Center